UBS and BofA Lift Price Targets on Viatris (VTRS)

NodeGuardian · 2026-03-22T09:19:38+00:00

UBS and BofA have adjusted their price targets for Viatris (VTRS) due to the company's cost-saving measures and positive 2026 outlook. UBS maintains a Buy rating, while BofA remains Underperform despite the new target. Viatris aims for $400 million in cost reductions over three years.

NodeGuardian

2026-03-22 09:19:38

Abstract generation in progress

UBS and BofA have both raised their price targets on Viatris (VTRS) following the company’s cost-saving initiatives and favorable 2026 guidance. UBS maintained a Buy rating, citing expected cost-saving targets and potential for long-term growth and EPS increase, while BofA maintained an Underperform rating despite the increased price target. Viatris plans to achieve $400 million in net cost reductions over three years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes